The documentation of an AI model must list the training datasets to enable the exercise of rights, according to the new
European Legislation. This simple regulatory line devalues algorithmic secrecy and makes data provenance the central strategic asset. The competitive moat is no longer the model. It's the data factory that feeds it.
Model Standardization, Data Friction
The algorithmic advantage is eroding at an accelerated pace. Cutting-edge architectures are published on arXiv and replicated within weeks. Open-source frameworks have democratized access to techniques that were once a competitive differentiator. The real barrier to entry in the healthcare sector remains the same: it's the acquisition, cleansing, and governance of clinical data at scale.
The challenge is not only technical, but also structural and regulatory. The European Health Data Area (EHDS) proposal requires entities to maintain public and machine-readable catalogs of their datasets, detailing their source and scope according to the Regulation (EU) 2025/327 — Article 77. This transforms data governance from a good engineering practice into a legal requirement for operation.
Integration into the real clinical environment introduces another layer of friction. Problems manifest themselves in the "last mile": a lack of appropriate software licenses for interoperability or deficiencies in support services for connecting with legacy hospital systems. These are infrastructure and process problems, not "deep learning" issues, as a 2020 report by the [unspecified organization] clearly details. Spanish Society of Health Informatics (SEIS).
Technical Reality: Beyond Precision
For CTOs, evaluating a medical AI system must go beyond laboratory metrics (AUC, F1 score). The system's robustness is defined by its data pipeline architecture, where the real engineering bottlenecks lie.
The first problem is generating a "golden dataset." High variability among specialists is a recurring issue. Two specialists may annotate the same clinical evidence differently, introducing noise into the labels that degrades the model's reliability. Building a pipeline to manage this disagreement—through consensus rounds, adjudication by a third expert, or uncertainty modeling—is a significant challenge. MLOps much more complex than fine-tuning a pre-trained model.
The second challenge is data acquisition architecture. There are two dominant paradigms, each with critical drawbacks:
1. Federated LearningThe model travels to the data, which remains in hospital silos. This minimizes the risk of data transfer under healthcare privacy frameworks (GDPR in the EU/HIPAA in the US) and facilitates collaboration with institutions reluctant to share. However, it introduces enormous orchestration complexity, faces problems with non-IID data (heterogeneous data distributions across hospitals), and slows down training cycles.
2. Centralization in Private CloudThe data is anonymized and moved to a controlled environment. This allows for faster harmonization and pre-processing, accelerating iteration. The cost is a concentrated regulatory and security risk, a greater burden in establishing data-sharing agreements, and CAPEX significantly higher initial.
Regulatory approval depends on the ability to defend this infrastructure. A company like Viz.ai o PathAI It doesn't just present its performance metrics to the regulator. It must provide comprehensive evidence of the traceability of its pipeline: how each piece of data was acquired, who recorded it, how it was versioned, and how its quality was ensured. The pipeline is not a support for the model; it is the product being audited.
The entire data pipeline, from source to training, is an industrial assembly line:
- IntakeConnectors for medical records y imaging systems from the hospital.
- Anonymization: Deletion of personal data and privacy controls (GDPR/HIPAA).
- Standardization: Unify formats (e.g., DICOM) and normalize fields so that everything “fits”.
- Expert labelingA tool for specialists mark cases and the quality is validated.
- Versioned: Record what data and what model were used in each version in order to repeat and audit results, a key governance practice according to the technical guide of Datos.gob.es (data version control).
Money: The Real Cost of Clinical Data
There are no consistent public benchmarks for the cost per image for acquiring and annotating medical data. However, anecdotal evidence from the industry suggests that the cost of annotating a single MRI scan by a certified radiologist in the US or Europe can significantly exceed the computational cost of training a model on thousands of already labeled images. This cost is the real capital drain.
Regulation imposes direct and structural costs. Regulation (EU) 2017/746 (IVDRIt requires that organizations developing regulated health products and systems comply with strict impartiality and confidentiality requirements. Staff cannot have financial interests that could affect their judgment, a rule that impacts the company's incentive structure.
Marketing in the EU requires CE marking and the management of unique product identifiers in official registers (Basic UDI-DI), according to the IVDR — Article 26 (UDI system). Certificates issued by notified bodies, as detailed in the IVDR — Article 51 (certificates from notified bodies), They add another layer of oversight and bureaucratic cost.
The ability to manage this compliance in a scalable way across multiple products does not reside in the R&D team, but in the maturity of the operational and data infrastructure.
The Opposite Bet: The Moat Is in the Data, Not the Model
The investment thesis for medical AI needs to pivot. Technical due diligence cannot focus on the novelty of the model, but rather on the robustness and scalability of the data infrastructure. Models are transient; the ability to continuously generate and validate new models in compliance with regulations is a lasting asset.
There are valid counterarguments. A disruptive algorithmic breakthrough could drastically reduce the need for data. Cloud platforms like AWS HealthLake are looking to make that infrastructure a standard service. And the hospital distribution and integration network could be an even deeper pitfall.
However, even with more efficient models, regulatory validation will still require high-quality, traceable data pipelines. Infrastructure is not a support cost; it is the primary strategic asset. Long-term competitive advantage will belong to those who build the most reliable data factory, not those who discover the most elegant algorithmic formula. It's a matter of industrial engineering, not alchemy.
Sources and References
- Artificial intelligence and health
- Artificial intelligence and the digitization of health
- IMPACT OF ARTIFICIAL INTELLIGENCE ON THE TRANSFORMATION OF HEALTHCARE: BENEFITS AND CHALLENGES
- Technical guide: Data version control
- Artificial Intelligence in Radiology: Current State and Future Projection in the Healthcare System…
- Office of Science and Technology of the Congress of Deputies. Report C. Graphic Summary: Artificial Intelligence and Health. 2022
- Artificial intelligence in healthcare
- Artificial intelligence in the healthcare sector: Promises and challenges
- Augmented reality and virtual reality in medical devices

Leave a Reply